Related Experiment Video
Updated: Jul 17, 2026
Workflow and Framework for Collecting and Implementing Point-of-Care Ultrasound Data in the Management of Heart Failure Patients
Published on: July 12, 2024
Update in the approach to and management of heart failure
1Division of Cardiovascular Medicine, University Hospitals, Cleveland, OH 44106, USA.
Insights
Optimal medical therapy can slow the progression of heart failure (HF). Key treatments include angiotensin-converting enzyme inhibitors (ACEIs) and beta blockers, with aldosterone antagonists improving mortality.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Heart failure (HF) is a widespread, serious chronic illness with distinct stages.
- Progression of HF can be mitigated through effective medical interventions.
Purpose of the Study:
- To outline the diagnostic and therapeutic strategies for managing patients with heart failure.
- To emphasize the importance of identifying underlying causes and managing comorbid conditions in HF.
Main Methods:
- Clinical diagnosis at the bedside.
- Serum brain natriuretic peptide (BNP) measurement for diagnostic uncertainty.
- Physical examination to assess hemodynamic status.
- Pharmacological interventions including ACEIs, beta blockers, ARBs, and aldosterone antagonists.
Main Results:
- ACEIs and beta blockers are foundational therapies for chronic HF.
- Aldosterone antagonists enhance survival but necessitate monitoring for hyperkalemia.
- ARBs serve as viable alternatives for patients intolerant to ACEIs.
- Digoxin offers symptomatic relief but not mortality benefit.
Conclusions:
- Effective HF management hinges on timely diagnosis, identifying the cause of left ventricular dysfunction, and assessing hemodynamic status.
- Aggressive treatment of comorbidities and consistent follow-up are crucial for slowing disease progression, optimizing function, and prolonging life.
Abstract:
Heart failure (HF) is a prevalent and morbid chronic disease that patients experience in stages. Progression through the stages of HF can be slowed with optimal medical therapy. Although HF remains a clinical diagnosis made at the bedside, measurement of serum brain natriuretic peptide (BNP) can help in the diagnosis when there is uncertainty. The initial workup for patients with newly diagnosed HF is directed at identifying the underlying cause of left ventricular dysfunction. An assessment of hemodynamic status, determined by a careful physical examination, can be used to direct therapy. Angiotensin-converting enzyme inhibitors (ACEIs) and beta blockers remain the two most important therapies for patients with chronic HF. Aldosterone antagonists improve mortality but require close monitoring for severe hyperkalemia. Angiotensin-receptor blockers (ARBs) are excellent alternatives to ACEIs for ACEI-intolerant patients. Digoxin, a second line agent in HF, improves symptoms without mortality benefit. Successful management of HF requires aggressive management of comorbid conditions and careful follow up to slow disease progression, optimize functional status, and improve longevity.
Related Concept Videos
01:30Heart Failure V: Medical Management
01:30Heart Failure VII: Nursing Interventions
01:22Heart Failure VI: Adjunct Therapies
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Heart Failure IV: Classification and Diagnostic Evaluation
01:29Cardiomyopathy V: Interprofessional Care